Correlations of <it>EGFR </it>mutations and increases in <it>EGFR </it>and <it>HER2 </it>copy number to gefitinib response in a retrospective analysis of lung cancer patients

Correlations of <it>EGFR </it>mutations and increases in <it>EGFR </it>and <it>HER2 </it>copy number to gefitinib response in a retrospective analysis of lung cancer patients

<p>Abstract</p> <p>Background</p> <p>Gefitinib, a small molecule tyrosine kinase inhibitor of the Epidermal Growth Factor Receptor (<it>EGFR</it>), has shown limited efficacy in the treatment of lung cancer. Recognized clinical predictors of response to this...

Full description

Bibliographic Details
Main Authors:	English John, Melosky Barbara, Murray Nevin, Ho Cheryl, O'Connor Robert, Salski Chris, Fee John, Sutcliffe Margaret, Barclay Lorena, Bebb Gwyn, Pugh Trevor J, Vielkind Jeurgen, Horsman Doug, Laskin Janessa J, Marra Marco A
Format:	Article
Language:	English
Published:	BMC 2007-07-01
Series:	BMC Cancer
Online Access:	http://www.biomedcentral.com/1471-2407/7/128

Similar Items

Gefitinib and EGFR gene copy number aberrations in esophageal cancer
by: Petty, RD, et al.
Published: (2017)

Beyond disease-progression: Clinical outcomes after EGFR-TKIs in a cohort of EGFR mutated NSCLC patients.
by: Roxana Alina Tudor, et al.
Published: (2017-01-01)

Role of Endocytosis Proteins in Gefitinib-Mediated EGFR Internalisation in Glioma Cells
by: Elisabete Cruz Da Silva, et al.
Published: (2021-11-01)

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
by: Wang Wen-Ping, et al.
Published: (2012-01-01)

The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer
by: C.L. Watkins, et al.
Published: (2010-09-01)

Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death
by: Colleen M. Britain, et al.
Published: (2018-02-01)

Real-World Clinical Outcomes for Patients with <i>EGFR</i> and <i>HER2</i> Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer
by: Kelly Li, et al.
Published: (2023-07-01)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
by: Yuan Ying, et al.
Published: (2012-11-01)

Gefitinib plus chemotherapy for EGFR-mutant non-small-cell lung cancer
by: Aman Chaudhary, et al.
Published: (2022-01-01)

Review of EGFR TKIs in metastatic NSCLC, including ongoing trials
by: Barbara eMelosky
Published: (2014-09-01)

Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R.
by: Chien-Hung Gow, et al.
Published: (2005-09-01)

Phenformin alone or combined with gefitinib inhibits bladder cancer via AMPK and EGFR pathways
by: Yanjun Huang, et al.
Published: (2018-07-01)

Efficacy of Gefitinib for Young Patients with Unknown EGFR Gene Mutation  in Advanced Lung Adenocarcinoma
by: Yutao LIU, et al.
Published: (2014-05-01)

Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments.
by: Debby D Wang, et al.
Published: (2015-01-01)

Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway
by: Pan YH, et al.
Published: (2018-08-01)

Selective Inhibition of AKT Protein Isoforms Augments Gefitinib Response in EGFR Mutated NSCLC Cells
by: Bokobza, S, et al.
Published: (2012)

Clinical research on the efficacy of self-made sichongsan in combination with gefitinib on NSCLC patients with EGFR mutation
by: Yibo Zhao, et al.
Published: (2018-06-01)

RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC
by: Makoto Nishio, MD, PhD, et al.
Published: (2022-04-01)

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
by: Kejun Liu, et al.
Published: (2020-01-01)

Relationship between EGFR Promoter Region Methylation and Secondary Resistance Which may be Induced by Gefitinib
by: Qilong WANG, et al.
Published: (2015-04-01)

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
by: Shu Y, et al.
Published: (2021-11-01)

Extracellular Vesicle miR-200c Enhances Gefitinib Sensitivity in Heterogeneous EGFR-Mutant NSCLC
by: Chien-Chung Lin, et al.
Published: (2021-02-01)

Knowledge-based mechanistic modeling accurately predicts disease progression with gefitinib in EGFR-mutant lung adenocarcinoma
by: Adèle L’Hostis, et al.
Published: (2023-07-01)

Gefitinib: a pharmacoeconomic profile of its use in patients with Non Small Cell Lung Cancer EGFR+
by: Viola Sacchi
Published: (2011-06-01)

Gefitinib and fostamatinib target EGFR and SYK to attenuate silicosis: a multi-omics study with drug exploration
by: Mingyao Wang, et al.
Published: (2022-05-01)

BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib
by: Niki Karachaliou, MD, PhD, et al.
Published: (2021-03-01)

Achievement of Cure with Gefitinib in Advanced Lung Adenocarcinoma Harboring an Activating EGFR Mutation: A Case Report
by: Taiji Kuwata, et al.
Published: (2016-10-01)

EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells
by: Hao Gong, et al.
Published: (2020-12-01)

How to Make the Choice in the Retreatment of EGFR-TKI for Advanced NSCLC Patients Who Benefited from Prior Gefitinib Therapy: the Original Drug or Switching to A Second EGFR-TKI?
by: Chuanhao TANG, et al.
Published: (2013-07-01)

Management of Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR-TKIs
by: Barbara eMelosky, et al.
Published: (2014-09-01)

Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas
by: Wu Shafei, et al.
Published: (2010-07-01)

LPIN1 Induces Gefitinib Resistance in EGFR Inhibitor-Resistant Non-Small Cell Lung Cancer Cells
by: Jung Hee Cho, et al.
Published: (2022-04-01)

EGFR Gene Mutation Statuses in Advanced Non-small Cell Lung Cancer Patients and Their Influence on Effect of Gefitinib
by: Wei ZHONG, et al.
Published: (2012-09-01)

Synergistic antitumor effect between gefitinib and fractionated irradiation in anaplastic oligodendrogliomas cannot be predicted by the Egfr signaling activity.
by: Sophie Pinel, et al.
Published: (2013-01-01)

Effect of rs2293347 Polymorphism in EGFR on the Clinical Efficacy of Gefitinib  in Patients with Non-small Cell Lung Cancer
by: Fei MA, et al.
Published: (2011-08-01)

Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells.
by: Yun-Ju Chen, et al.
Published: (2011-01-01)

Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line
by: Bereczky Biborka, et al.
Published: (2008-05-01)

Leucine Zipper Downregulated in Cancer-1 Interacts with Clathrin Adaptors to Control Epidermal Growth Factor Receptor (EGFR) Internalization and Gefitinib Response in EGFR-Mutated Non-Small Cell Lung Cancer
by: Hsien-Neng Huang, et al.
Published: (2024-01-01)

Response to gefitinib/crizotinib combination in a pulmonary sarcomatoid carcinoma patient harboring concurrent EGFR mutation and MET amplification
by: Xiaomeng Wang, et al.
Published: (2021-07-01)

BST2 promotes growth and induces gefitinib resistance in oral squamous cell carcinoma via regulating the EGFR pathway
by: Huang Jin, et al.
Published: (2019-07-01)